In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 171 to 180 of 294

TitleTypeExpected publication date
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]Technology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Technology appraisal guidanceTBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]Technology appraisal guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
Orforglipron for managing overweight and obesity [ID6516]Technology appraisal guidance
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All